Kinase News and Research

RSS

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.

16 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

Research sheds light on how protein keeps people organized by promoting orderly skeletal growth

Most people think that their planners or their iPhones keep them organized, when proteins such as liver kinase b1 (Lkb1) actually have a lot more to do with it. New research from postdoctoral fellow Lick Lai in the lab of USC scientist Andy McMahon published in Proceedings of the National Academy of Sciences (PNAS) sheds light on how this important protein keeps people organized on a basic level by promoting orderly skeletal growth and preventing skeletal tumors.

15 Nov 2013

FDA approves ibrutinib for treatment of mantle cell lymphoma

Today's U.S. Food and Drug Administration approval of ibrutinib to treat patients with mantle cell lymphoma is a significant advance for patients with this blood cancer. It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy.

14 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Novel approach confirms dysfunctional energy production in schizophrenia

A method of directly assessing creatine kinase in the brain provides “direct and compelling” evidence for abnormal bioenergetics in the brains of patients with schizophrenia, say the study authors.

12 Nov 2013

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.

11 Nov 2013

New zebrafish technique finds potential treatments for multiple diseases

Skeletal muscle has proved to be very difficult to grow in patients with muscular dystrophy and other disorders that degrade and weaken muscle. Researchers at Boston Children's Hospital's Stem Cell Program now report boosting muscle mass and reversing disease in a mouse model of Duchenne muscular dystrophy, using a "cocktail" of three compounds identified through a new rapid culture system. Adding the same compounds to stem cells derived from patients' skin cells, they then successfully grew human muscle cells in a dish.

8 Nov 2013

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.

8 Nov 2013

Inhibition of heart protein reduces damage from heart attack, say researchers

The stop and start of blood flow to the heart during and after a heart attack causes severe damage to heart cells, reducing their capacity to function and potentially causing their death.

7 Nov 2013

New study could help lead to prevention and treatment of heart failure in diabetics

Researchers from the University of Texas Medical Branch at Galveston have discovered one of the pathogenic components of diabetes in the heart, as published in the Journal of Biological Chemistry.

7 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

Scientists investigate combined action of two different compounds against CML

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.

6 Nov 2013

Researchers on the way to find cure against African sleeping sickness

Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, which will be publicly defended on 8 November 2013.

6 Nov 2013

McMaster University researchers discover how metformin drug works on fat in the liver

About 120 million people around the world with Type 2 diabetes - and two million in Canada - take the drug metformin to control their disease.

4 Nov 2013

Study: Dual-pronged strategy could successfully treat childhood cancer

A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study.

3 Nov 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Reduced SMG1 protein expression may contribute to neurological disorders

The absence of a protein called SMG1 could be a contributing factor in the development of Parkinson's disease and other related neurological disorders, according to a study led by the Translational Genomics Research Institute.

31 Oct 2013

Brain-derived neurotrophic factor may inhibit glucose intolerance after cerebral ischemia

Interestingly, a recent study found that ischemic stress causes hyperglycemia and may worsen ischemic neuronal damage. In addition, decreased insulin sensitivity after ischemic stress seems to be involved in the development of post-ischemic glucose intolerance.

30 Oct 2013

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

Kinase News and Research

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

Research sheds light on how protein keeps people organized by promoting orderly skeletal growth

FDA approves ibrutinib for treatment of mantle cell lymphoma

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Novel approach confirms dysfunctional energy production in schizophrenia

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

New zebrafish technique finds potential treatments for multiple diseases

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

Inhibition of heart protein reduces damage from heart attack, say researchers

New study could help lead to prevention and treatment of heart failure in diabetics

New drug combination therapy effectively kills cancer cells

Scientists investigate combined action of two different compounds against CML

Researchers on the way to find cure against African sleeping sickness

McMaster University researchers discover how metformin drug works on fat in the liver

Study: Dual-pronged strategy could successfully treat childhood cancer

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Reduced SMG1 protein expression may contribute to neurological disorders

Brain-derived neurotrophic factor may inhibit glucose intolerance after cerebral ischemia

Janssen submits Marketing Authorization Application for Ibrutinib

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News